Skip to content

Study · In silico · 2024

6 results

Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.

Hu S, Shi C, Ma Y, Wang S, Gu S, Qi C, Fan G

Diabetes, obesity & metabolism13 May 2024Cited by 3 (Europe PMC)

PMID38738340 (opens in a new tab)DOI10.1111/dom.15645 (opens in a new tab)PepBankPUB-38738340
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoOther

    In a lifetime simulation for type 2 diabetes, quality-adjusted life years were 11.17, 11.21 and 11.27 years for tirzepatide 5, 10 and 15 mg.

    In plain wordsIn a computer simulation, tirzepatide gave 11.17 to 11.27 quality-adjusted life years, depending on dose.

    Peptide
    Tirzepatide
    Outcome
    Not applicableQuality-adjusted life years (lifetime simulation)
    Study

    n: not reported in source

    Comparator
    Semaglutide 1 mg
    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    5, 10, 15 mgAs given in this study.

    Measurements

    QALYs
    11.17 years
    TIRZ 5 mg
    QALYs
    11.21 years
    TIRZ 10 mg
    QALYs
    11.27 years
    TIRZ 15 mg

    Source sentences

    Summary
    After lifetime simulation, the quality-adjusted life years of TIRZ 5, 10, 15 mg and SEMA 1 mg were 11.17, 11.21, 11.27 and 11.12 years, respectively.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.
  2. 02Computer modelIn silicoOther

    In a lifetime simulation for type 2 diabetes, quality-adjusted life years were 11.12 years for semaglutide 1 mg.

    In plain wordsIn a computer simulation, semaglutide gave 11.12 quality-adjusted life years.

    Peptide
    Semaglutide
    Outcome
    Not applicableQuality-adjusted life years (lifetime simulation)
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    1 mgAs given in this study.

    Measurements

    QALYs
    11.12 years
    SEMA 1 mg

    Source sentences

    Summary
    After lifetime simulation, the quality-adjusted life years of TIRZ 5, 10, 15 mg and SEMA 1 mg were 11.17, 11.21, 11.27 and 11.12 years, respectively.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.
  3. 03Computer modelIn silicoOther

    In China, tirzepatide was probably more cost-effective than semaglutide when the annual costs were assumed equal.

    In plain wordsIn a computer model for China, tirzepatide was probably better value than semaglutide at the same yearly cost.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost-effectiveness versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite an initial assumption that the annual cost of TIRZ equals that of SEMA, our analysis revealed that TIRZ is probably more cost-effective than SEMA.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.
  4. 04Computer modelIn silicoOther

    The cost ranges for tirzepatide at 5, 10 and 15 mg were $1628.61-$1846.23, $1738.40-$2140.95 and $1800.30-$2430.81, respectively.

    In plain wordsThe model gave price ranges for tirzepatide that would match semaglutide on cost-effectiveness, for each of the three doses.

    Peptide
    Tirzepatide
    Outcome
    Not applicableMost matchable price of tirzepatide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    5, 10, 15 mgAs given in this study.

    Source sentences

    Summary
    A thorough evaluation of pricing showed that the cost ranges for TIRZ at doses of 5, 10 and 15 mg were $1628.61-$1846.23, $1738.40-$2140.95 and $1800.30-$2430.81, respectively.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.
  5. 05Computer modelIn silicoOther

    After adjustment in the univariate sensitivity analysis, the cost ranges for tirzepatide 5, 10 and 15 mg were $1542.68-$1757.57, $1573.00-$1967.16 and $1576.54-$2133.96, respectively.

    In plain wordsAfter a sensitivity check, the model gave adjusted price ranges for each tirzepatide dose.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePrice ranges after sensitivity adjustment
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    5, 10, 15 mgAs given in this study.

    Source sentences

    Summary
    After adjustment in the univariate sensitivity analysis, the cost ranges for TIRZ 5, 10 and 15 mg were $1542.68-$1757.57, $1573.00-$1967.16 and $1576.54-$2133.96, respectively.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.
  6. 06Computer modelIn silicoOther

    The cost intervals were validated by probabilistic sensitivity and scenario analysis, except for the cost range for tirzepatide 5 mg.

    In plain wordsExtra model checks confirmed the price ranges for the 10 mg and 15 mg doses but not for the 5 mg dose.

    Peptide
    Tirzepatide
    Outcome
    Not applicableValidation of price ranges
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cost-effectiveness · Metabolic and weight
    Studied dose
    5, 10, 15 mgAs given in this study.

    Source sentences

    Summary
    These cost intervals were validated through robust probabilistic sensitivity analysis and scenario analysis, except for the cost range for TIRZ 5 mg.
    1 context sentence
    Summary · context
    The patient cohort and clinical efficacy data were derived from the SURPASS-2 trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.